Sumitomo Pharma America enters into a Cooperative Research and Development Agreement with the National Cancer Institute to Advance Clinical Understanding of Enzomenib
– Partnership with the NCI will build on the promising preliminary clinical activity of enzomenib in acute leukemia to further explore potential activity in other cancers –